Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Rhea-AI Summary
Taysha Gene Therapies (Nasdaq: TSHA) and Catalent have expanded their strategic partnership with a commercial supply agreement for TSHA-102, Taysha’s investigational AAV-based gene therapy in pivotal development for Rett syndrome. Under the agreement, Catalent will serve as Taysha’s primary commercial manufacturer following potential U.S. FDA approval.
The deal secures long-term GMP manufacturing capacity and a scalable supply framework at Catalent’s FDA-licensed gene therapy facility in Harmans, Maryland, which supports more than 90 gene therapy programs, including multiple commercial products. Taysha reports that BLA-enabling Process Performance Qualification activities for TSHA-102 are underway, aligning manufacturing readiness with a potential future commercial launch.
Positive
- Commercial supply agreement designating Catalent as primary manufacturer for TSHA-102 post potential FDA approval
- Long-term GMP capacity secured at Catalent’s FDA-licensed Harmans, Maryland gene therapy facility
- BLA-enabling Process Performance Qualification activities for TSHA-102 reported as underway
- Manufacturing framework designed to support potential launch and future demand for TSHA-102
Negative
- TSHA-102 remains an investigational therapy and is dependent on potential future U.S. FDA approval before commercialization
News Market Reaction – TSHA
In the Aug 3 session, TSHA declined 1.37%, reflecting a mild negative market reaction. Argus tracked a peak move of +10.6% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Program presentations | Neutral | +2.1% | Planned TSHA-102 clinical and preclinical presentations at the Rett Syndrome Scientific Meeting |
| Jun 24 | Public offering | Negative | -10.5% | Pricing of common shares and pre-funded warrants generated approximately $200 million |
| Jun 24 | Public offering | Negative | -10.5% | Proposed approximately $200 million offering included common stock and pre-funded warrants |
| Jun 22 | Clinical trial update | Positive | +1.7% | REVEAL pivotal dosing completed and longer-term TSHA-102 clinical data reported |
| Jun 05 | Equity inducement grant | Negative | -6.6% | Equity awards were granted to four new employees under Nasdaq Listing Rule 5635(c)(4) |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news generally aligned with the stock's subsequent direction, while the latest offering announcements were followed by the largest negative moves.
Key Terms
aav medical
cdmo technical
gmp manufacturing technical
bla-enabling regulatory
process performance qualification technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic diseases of the central nervous system, and Catalent, Inc., (Catalent), the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced a commercial supply agreement for TSHA-102, Taysha’s investigational gene therapy in pivotal development for Rett syndrome, under which Catalent will serve as Taysha’s primary commercial manufacturer following potential U.S. Food and Drug Administration (FDA) approval.
Building on a partnership that has supported the development of TSHA-102 since 2020, the agreement secures long-term commercial manufacturing capacity and a scalable supply framework to support a potential commercial launch and future demand. Catalent will provide GMP manufacturing and commercial supply of TSHA-102 at its FDA-licensed commercial gene therapy facility in Harmans, Maryland, leveraging its experience across more than 90 gene therapy programs, including multiple commercial products.
“As we continue to advance TSHA-102, establishing long-term commercial manufacturing capacity is a critical component of our launch readiness strategy,” said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. “Catalent's deep gene therapy expertise and proven commercial manufacturing capabilities make them an ideal partner as we expand our partnership to further strengthen our commercial infrastructure with a reliable, scalable supply framework. With BLA-enabling Process Performance Qualification activities underway, we believe we have established the manufacturing foundation necessary to support the strong demand we expect following the potential launch and commercialization of TSHA-102.”
“At Catalent, our priority is to support innovators who are redefining what’s possible for patients with rare diseases,” said David McErlane, Biologics Group President for Catalent. “Our partnership with Taysha brings together deep AAV expertise and a shared commitment to advancing a potential therapy for Rett syndrome—a condition with significant unmet need. We are proud to help enable the development and future supply of therapies that have the potential to make a meaningful difference for patients and their families.”
This partnership reflects Catalent’s continued commitment to supporting innovators across the cell and gene therapy landscape, providing end-to-end solutions from development through commercialization to help bring transformative therapies to patients.
About Rett Syndrome
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
About Catalent
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development and regulatory plans for its product candidates; the potential demand for TSHA-102; and the ability of the agreement between Taysha and Catalent to secure long-term commercial manufacturing capacity and a scalable supply framework for the commercial supply of TSHA-102. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in its SEC filings, including in Taysha’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which is available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.
Taysha Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Taysha Media Contact:
media@tayshagtx.com
Catalent Media Contact:
media@catalent.com
